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INTRODUCTION 
Post partum hemorrhage is one of the leading causes of maternal mortality in both the developed and developing world (3, 4). Post partum hemorrhage is 
caused by the loss of blood from the uterus following 
labor due to decreased uterine tone, retained placenta or 
placental fragments, as well as lower genital tract trauma 
(5). Routine management of post partum hemorrhage 
involves the use of parenteral oxytocin (OT) to increase 
uterine tone and reduce bleeding and is administered via 
the intramuscular or intravenous route. However, OT is 
rapidly metabolized in the liver and cleared from the body 
via the kidney (6). The use of a long-acting parenteral 
preparation of OT to maintain uterine tone would be 
useful as a means of reducing maternal mortality by 
preventing post partum hemorrhage.
Pluronic® 127 (PF-127) is an amphiphilic block 
copolymer that, when dissolved in water, exists as a 
viscous liquid at low temperatures (2–8 °C) and forms a 
stiff gel when warmed (7, 8). The thermo-gelling behavior 
of PF-127 means that at low temperatures, the sample is 
free-flowing, allowing relatively easy administration of a 
PF-127 based formulation using a syringe and a needle. 
The stiff gel that is formed in situ at body temperatures 
would produce a potential depot delivery vehicle for the 
sustained delivery of drugs such as proteins and peptides.
In vitro drug dissolution and release testing is used to 
generate vital information primarily for quality control 
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ABSTRACT
The objective of these studies was to develop a discriminatory in vitro release test for assessing formulation factors 
that may affect oxytocin (OT) release during formulation development studies of a Pluronic® F127 OT in situ gel-forming 
parenteral dosage form. An appropriate release assessment method should be able to discriminate between the 
performance of different formulation compositions (1, 2), and this was the primary criterion used for selection of an 
appropriate test procedure during the test method development process. ANOVA and the difference (f1) and similarity (f2) 
factors were used to evaluate the discriminatory behavior of different test methods that were investigated in these 
studies. The in vitro release tests that were investigated included the use of USP Apparatus 1, 2, and 3; a dialysis bag in USP 
Apparatus 2; and a membrane-less diffusion method. It was concluded that the use of USP Apparatus 3 was best able to 
discriminate between OT release for the different formulations tested. USP Apparatus 3 was thus considered the most 
suitable in vitro release test apparatus for studying formulation factors affecting OT release during the development of a 
parenteral dosage form prepared using Pluronic® F127.
purposes, batch uniformity assessment, and evaluating 
batch-to-batch variability. In the context of pharmaceuti-
cal research and development, prediction of in vivo 
behavior of dosage forms and assessment of the impact of 
formulation changes or method of manufacture on overall 
dosage form performance in vivo may be inferred from 
dissolution profiles (9). 
The intrinsic variability of in vitro release testing 
warrants careful method development for a test to reflect 
the true drug release characteristics from any drug 
delivery system. The type of drug and apparatus that are 
used must be carefully considered, since these factors can 
influence the rate and extent of drug release obtained 
during in vitro release testing (10). The selection of an in 
vitro release method and dissolution medium must allow 
for the prediction of an in vitro–in vivo correlation for the 
ultimate method of choice, if at all possible (11).
There are no accepted compendial guidelines for in 
vitro testing to assess drug release for controlled and 
sustained release parenteral formulations, such as those 
made from PF-127, for example. The United States 
Pharmacopeia (12) provides guidance for dissolution 
testing of oral and transdermal dosage forms but not 
for assessing the in vitro release of an active ingredient 
from controlled release parenteral preparations. 
Guidelines for the evaluation of novel delivery systems 
such as orally disintegrating and chewable tablets have 
been reported, although recommendations for controlled 
release parenteral formulations have not yet been 
established. However, the use of compendial and modified 
flow-thorough cell apparatus for assessment of sustained 1Corresponding author.
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release parenteral formulations has been applied with 
some success (2). The selection of an appropriate 
apparatus for in vitro release testing of controlled release 
parenteral systems, including microparticulate, nanopar-
ticulate, hydrogel, and liposomal dosage forms, has been 
the subject of several conferences and publications (1, 2, 
11, 13, 14). Mechanistic models for the release of active 
pharmaceutical ingredients (API) from semi-solid dosage 
forms such as those manufactured using PF-127 (15) and 
gelatin-alginate matrices (16) have been reported. API 
release followed near zero-order kinetics for PF-127 
systems containing methotrexate (15), whereas when 
gelatin-alginate matrices were used, first-order release 
kinetics were observed (16). These reports are useful for 
the analysis of API release mechanisms from such systems; 
however, the impact of different test methods and the 
use of statistical comparisons in the selection of an 
appropriate in vitro test method were not investigated. 
The comparison of in vitro release profiles can be 
achieved by the use of mathematical methods of analysis. 
Mathematical analysis for the assessment of in vitro 
release profiles can be divided into 3 types: model-
dependent (curve fitting) methods, model-independent 
methods, and statistical analysis (17). 
Statistical methods have been used for the evaluation 
and comparison of dissolution profiles following in vitro 
dissolution testing (18, 19) and for development and 
optimization of in vitro dissolution tests (20–22). Statistical 
methods can be used to compare different formulations 
tested under the same experimental conditions and to 
compare dissolution tests for the same formulation tested 
under different test conditions (17, 20, 22). 
Analysis of variance methods can be differentiated as 
univariate or one-way analysis of variance (ANOVA) and 
multivariate analysis of variance (MANOVA). ANOVA tests 
may be used to assess the difference between the means 
of two dissolution or drug release data sets in single time 
point dissolution tests, and MANOVA analysis is useful for 
the evaluation of multiple time point dissolution tests 
(17). It has been reported that ANOVA analysis is more 
informative and easier to interpret than MANOVA analysis, 
which requires data transformation on repeated measures 
and makes interpretation of results difficult (19). 
To compare in vitro dissolution release profiles, a 
repeated measures design may be used, where the 
percent drug dissolved is the dependent variable and time 
the repeated factor. Univariate ANOVA analysis can be 
applied to each time point when comparing dissolution 
profiles to determine where differences, if any, exist 
between the dissolution profiles being compared (19). 
Different post hoc tests including the least significant 
difference test, Tukey’s multiple range test, Scheffé 
method, Newman-Keuls test, and Dunnett’s test can be 
used to determine the exact points of difference between 
dissolution profiles of test products (23). ANOVA-based 
methods of analysis reveal information about differences 
in the shape and levels of different dissolution data sets 
that are being compared (19), although they have been 
criticized for being too discriminatory, showing statistical 
differences in dissolution profiles that may not necessarily 
reflect pharmaceutical differences (18). 
The difference (f1) and similarity (f2) factors may be used 
for the comparison of dissolution profiles (24). The f1 factor 
measures the percent error between dissolution profiles 
of a test and reference product at all time points. The 
percent error is zero when the in vitro release profiles of 
the test and reference product are identical, and this value 
increases as dissolution profiles become dissimilar. The f2 
factor is a logarithmic transformation of the sum-squared 
error of the differences between a test and reference 
product over all time points. The factor falls between 0 and 
100, and a value of 100 indicates that the dissolution 
profiles are identical (24). The difference and similarity 
factors cannot be applied to the evaluation of the same 
formulation under different experimental conditions, and 
fit factors have been reported to be of use during the 
development of an appropriate in vitro dissolution release 
test (21, 25). 
The objective of these studies was to develop a 
discriminatory in vitro release method for an OT parenteral 
formulation prepared using Pluronic® F127 as a 
gel-forming matrix. Different compendial test apparatus 
and an in-house in vitro release method were used. 
ANOVA and the f1 and f2 factors were used to assess the 
discriminatory ability of each of the test methods that 
were assessed. Furthermore, the selection of an 
appropriate dissolution test method would also consider 
the apparent ease of use and the ability to further 
optimize the method by adjusting the pH and speed of 
rotation or agitation, where applicable. 
MATERIALS AND METHODS
Materials
PF-127 was donated by BASF (Lot number WPIA571B) 
(Ludwigshafen, Germany) and used as received. Oxytocin 
(Lot number oxt 051210) was purchased from Inter-
Chemical Hongkong Ltd (Shenzhen, China) and had a 
potency of 470 IU/mg. HPLC grade water was purified 
using a Milli-Ro®-15 water purification system (Millipore, 
Bedford, MA, USA). The water was filtered through a 
0.22-µm Millipak® stack filter prior to use (Millipore, 
Bedford, MA, USA). 
Preparation of the Dosage Form
The preparation of OT-containing PF-127 dosage forms 
was undertaken using a modification of the “cold method” 
as previously described by Schmolka (7). The solutions of 
PF-127 were prepared by weight so as to contain 20%, 
25%, and 30% w/w of the polymer. Appropriate amounts 
of PF-127 flakes were weighed and added slowly to 
a previously cooled (5 °C) aqueous solution of OT 
(200 IU/mL) over a period of about 2–3 min with gentle 
stirring using a LabconTM MSH 10 magnetic stirrer 
(Labmark, Maraisburg, South Africa). The solution was then 
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placed in a refrigerator for approximately 24 hours or until 
all the PF-127 had dissolved and the solution was clear on 
visual inspection. The solutions were assayed for OT 
content using a previously validated HPLC method (26) 
before use, and the gels were set in molds of dimensions 
23.6 × 11.0 × 8.0 mm (L × W × D) such that only one 
surface of the gel was exposed to the dissolution test 
medium. An appropriate amount of gel was weighed 
such that each dosage unit to be tested contained 
approximately 300 IU of OT, and the gels were set in a 
Gallenkamp drying cabinet (Weiss Gallenkamp, 
Loughborough, United Kingdom) for 30 min at 37 °C prior 
to in vitro release testing. All release tests were performed 
on three dosage units (n = 3).
Dissolution Test Conditions
Preparation of the In Vitro Release Medium 
The dissolution medium was a 0.1 M phosphate buffer 
(pH = 7.2). The buffer was prepared by dissolving 68 g of 
potassium dihydrogen phosphate and adjusting the pH to 
7.2 using sodium hydroxide pellets. This medium was used 
for all experiments.
USP Apparatus 1 and 2
In vitro dissolution release testing with the basket (USP 
Apparatus 1) and paddle (USP Apparatus 2) apparatus was 
conducted using a fully automated Hanson Research SR 8 
PLUS™ dissolution tester fitted with an AutoplusTM, 
MultifillTM, and Maximizer Syringe Fraction Collector 
(Hanson Research Cooperation, Chatsworth, CA, USA). 
The dissolution medium (500 mL) was maintained at 
37 + 0.5 °C. The baskets (40 mesh) and the paddles were 
rotated at 25 rpm for the duration of the experiments. 
A low rpm was selected to minimize the hydrodynamic 
agitation in the system. Low agitation rates are expected 
in vivo since the intended route of administration is by 
intramuscular injection. The gels, retained in the molds, 
were placed in either the basket or at the bottom of a 
dissolution vessel when using USP Apparatus 1 or 2, 
respectively. Sample aliquots (1.5 mL) were withdrawn for 
analysis at 0, 30, 60, 90, 120, 180, 240, 360, and 480 min, and 
an equivalent amount (1.5 mL) of fresh dissolution 
medium was replaced automatically. 
USP Apparatus 3
The VanKel® Bio-Dis® dissolution tester (VanKel® 
industries, New Jersey, USA) was used. Temperature was 
maintained at 37 + 0.5 °C using a model VK 750D digitally 
controlled water heater/circulator (VanKel® industries, 
New Jersey, USA). A dissolution media volume of 180 mL 
was used in these studies. A 177-µm pore size screen mesh 
was used to retain the dosage form in the inner tube, and 
a 5-dpm dip speed provided agitation. The dosage form 
was moved through the different rows of dissolution 
vessels at 30, 60, 120, 240, and 360 min, and testing was 
maintained in the final row until the end of the dissolution 
test at 480 min. 
Dialysis Tubing Method
A 25-mm flat width dialysis tubing cellulose membrane 
(Sigma Aldrich, St Louis, MO, USA) was hydrated prior to 
use. One end of the dialysis tubing was tied, and an 
appropriate amount of OT-containing PF-127 gel was 
weighed and placed in the tube, such that there was 
approximately 300 IU in each dosage unit. The tube was 
then carefully tied at the other end. The gel was allowed to 
set in a convection oven (Weiss Gallenkamp, 
Loughborough, United Kingdom) at 37 °C for 30 min prior 
to commencing the test. The dialysis tubing containing 
the pre-set gel was placed in USP Apparatus 2 using 
500 mL of dissolution medium and agitated at 50 rpm. The 
dissolution medium was used to assess drug release, and 
samples were harvested at 30, 60, 120, 240, 360, and 480 
min. 
Membrane-Less Diffusion System
Appropriate amounts of each gel of different polymer 
composition (equivalent to 300 IU) were weighed and 
placed into 5-mL test tubes. The gels were allowed to set 
in a Grant Instruments (Cambridge Ltd, Cambridge, UK) 
water bath maintained at 37 °C. Dissolution medium 
(500 µL) was carefully placed on the surface of the gel, and 
the tubes were placed in the water bath for the duration 
of the study. Figure 1 shows a schematic diagram of the 
dissolution method that was employed. At predetermined 
times of 0, 30, 60, 90, 120, 180, 240, 360, and 480 min, the 
receptor fluid was removed completely and replaced with 
fresh receptor fluid. The sample solution was diluted and 
analyzed by HPLC. 
HPLC System 
The analytical method used for the in vitro assessment 
of OT dosage forms was previously reported (26). The 
system consisted of a Model P100 dual-piston solvent 
delivery module (Thermo Separation Products, San Jose, 
CA, USA), a Model AS100 autosampler (Thermo Separation 
Products, San Jose, CA, USA) fitted with a Rheodyne® 
Model 7010 injector (Rheodyne, Reno, Nevada, USA) and a 
fixed-volume 20-µL loop, and a Model 1725 GASTIGHT® 
Figure 1. Schematic representation of the membrane-less diffusion system. 
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250-µL syringe (Hamilton Co., Reno, NV, USA). A 
Phenomenex Hypersil® column, 5-µm, 4.6 × 150 mm 
(Phenomenex, Torrance, CA, USA) was used at ambient 
temperature (22 °C). The separation was conducted under 
isocratic conditions using a mobile phase consisting of 
20% v/v acetonitrile in 80 mM phosphate buffer at a flow 
rate of 1.5 mL/min with UV detection at 220 nm using a 
Linear UV/VIS-500 Model 6200-9060 detector (Linear 
Instrument Co., CA, USA). Data was collected using a 
Spectra Physics SP 4600 integrator (Thermo Separation 
Products, San Jose, CA, USA). The injection volume was 
20 µL.
Mathematical Treatment of In Vitro Release Data
The different test methods that were used to evaluate 
OT release from PF-127 gels were assessed for potential 
discriminatory behavior using ANOVA analysis and 
model-independent methods. In addition, the similarity of 
dissolution profiles for OT release from PF-127 dosage 
forms containing different concentrations of gel former 
was also evaluated. Univariate ANOVA analysis was 
performed using GraphPad Prism software Version 4.00 for 
Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com) to assess whether differences 
between each time point of the dissolution profiles 
existed for each of the formulations tested. Tukey’s 
multiple range test was used as a post hoc test to assess 
which of the formulations were different at the individual 
time points evaluated during the dissolution tests. 
Model-independent approaches that were used to assess 
the similarity or difference between in vitro dissolution 
profiles were the difference (f1) and similarity (f2) factors. 
Formulations were considered different if the f1 and f2 
factors were > 15 and < 50, respectively.
RESULTS AND DISCUSSION 
In Vitro Release Profiles of OT from the Different Test 
Methods
The in vitro release profiles for OT from PF-127 gels 
using the different test methods are shown in Figure 2. 
As expected, the rate of OT release from the different 
formulations tested was dependent on the formulation 
concentration of PF-127, with lower concentrations 
producing the fastest rate of release. The trend was 
observed for all dissolution apparatus tested. Formulations 
with low gel content have a lower viscosity than 
formulations with higher gel content and undergo faster 
gel dissolution. This effect ultimately results in a faster 
rate of OT liberation, and these findings are supported by 
other studies that have shown that the rate of release of a 
drug from PF-127 systems is controlled by the rate of 
dissolution of the gel (27, 28). 
ANOVA of the Different Test Methods
To establish which of the test methods, if any, were 
discriminatory, analysis of variance (ANOVA) was used to 
compare the release profiles of OT from the different 
Figure 2. The extent of OT release (n = 3) from PF-127 gels using (A) USP 
Apparatus 1, (B) USP Apparatus 2, (C) USP Apparatus 3, (D) Dialysis bag in 
USP Apparatus 2, and (E) Membrane-less diffusion methods. ---- 20% w/w 
PF-127, ---- 25% w/w PF-125 and ---- 30% w/w PF-127. 
formulations using different methods. The primary 
advantage of using ANOVA for this purpose is that it 
allows for the detection of differences at individual time 
points. Furthermore, ANOVA allows for careful monitoring 
of the profiles to determine if there are any changes in the 
discriminatory pattern of a test system as testing 
proceeds. The ANOVA results comparing the in vitro 
release profiles for each apparatus and formulation are 
summarized in Tables 1–5. 
ANOVA results for data generated using USP Apparatus 
1 are summarized in Table 1. For the initial 30 min of the 
dissolution test, there was no discrimination between the 
25% PF-127 formulation and both the 20% and 30% 
formulations, although discrimination was observed 
between the extremes of gel concentration (i.e., between 
the 20% and 30% gels). However, between 60 and 120 min, 
it can be seen from ANOVA results and visual inspection of 
the dissolution profiles (Figure 2A) that the three curves 
corresponding to the different concentrations of PF-127 
are separated from one other. In the later stage dissolution 
testing using USP Apparatus 1, the ANOVA results indicate 
that there were no significant differences between the in 
vitro release profiles that were obtained from the 20% 
and 25% formulations, although the 30% formulation 
can be visually discriminated from both the lower and 
intermediate PF-127 formulations.
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Table 1. ANOVA Results and Post Hoc Summary for In Vitro Release Profiles Generated Using USP Apparatus 1.
     95% Confidence interval to mean difference
Time (min) Comparison Mean difference Lower limit Upper limit P value Summary
30 20% vs. 25% 0.3021 –0.5800  1.184 P > 0.05 Not sig.
 20% vs. 30% 0.9569 0.07475 1.839 P < 0.05 Sig.
 25% vs. 30% 0.6548 –0.2274 1.537 P > 0.05 Not sig.
60 20% vs. 25% 1.665 0.2874 3.043 P < 0.05 Sig. 
 20% vs. 30% 4.939 3.561 6.317 P < 0.01 Sig.
 25% vs. 30% 3.274 1.896 4.652 P < 0.01 Sig.
90 20% vs. 25% 2.961 1.734 4.189 P < 0.01 Sig.
 20% vs. 30% 8.594 7.367 4.189 P < 0.001 Sig.
 25% vs. 30% 8.594 4.406 6.860 P < 0.001 Sig.
120 20% vs. 25% 2.903 –1.890 7.696 P > 0.05 Not sig.
 20% vs. 30% 9.846 5.053 14.64 P < 0.01 Sig.
 25% vs. 30% 6.943 2.150 11.74 P < 0.05 Sig.
180 20% vs. 25% 4.612 –4.439 13.66 P > 0.05 Not sig.
 20% vs. 30% 14.15 5.098 23.20 P < 0.05 Sig.
 25% vs. 30% 9.537 0.4866 18.59 P < 0.05 Sig.
240 20% vs. 25% 2.146 –10.40 14.69 P > 0.05 Not sig.
 20% vs. 30% 15.37 2.822 27.91 P < 0.05 Sig.
 25% vs. 30% 13.22 0.6752 25.77 P < 0.05 Sig.
360 20% vs. 25% 2.983 –5.357 11.32 P > 0.05 Not sig.
 20% vs. 30% 20.31 11.97 28.65 P < 0.01 Sig.
 25% vs. 30% 17.33 8.987 25.67 P < 0.01 Sig.
480 20% vs. 25% 2.058 –3.278 7.394 P > 0.05 Not sig.
 20% vs. 30% 17.57 12.24 22.91 P < 0.01 Sig.
 25% vs. 30% 15.52 10.18 20.85 P < 0.01 Sig.
ANOVA results reveal that the use of USP Apparatus 2 
(Table 2) does not show discrimination between the 
formulations tested and that no significant differences 
exist between the dissolution profiles when using these 
data. Visual inspection of Figure 2B clearly shows that the 
early and late segments of the in vitro release profiles are 
very close together. However, ANOVA results show 
differences between the 20% and 30% PF-127 
formulations at the early and late sample time points in 
the release profiles and no discrimination between the 
25% formulation and the 20% and 30% formulations. 
ANOVA results for the comparison of the release profiles 
generated using USP Apparatus 3 are reported in Table 3. 
The data indicate that significant differences exist in the 
percent OT dissolved at different time points in the early 
stages of test procedure, specifically between 0 and 
240 min. Thereafter, a plateau is reached for the 20% and 
25% formulations, and no significant differences are 
observed between the OT release profiles. 
The dialysis method results indicate that there are no 
significant differences between the 25% and both the 20% 
and 30% formulations for the majority of the time points 
tested; the data are summarized in Table 4. However, 
discrimination was achieved between the 20% and 30% 
formulations for all time points using this release method. 
The results from membrane-less diffusion indicate that 
the in vitro release profiles are different for the majority of 
time points tested. Significant differences between the 
means were observed according to the ANOVA performed 
and are summarized in Table 5. Visual inspection of the 
dissolution profiles shown in Figure 2E confirm these 
observations since the release profiles for the different 
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formulations are clearly well distinguished from each 
other.
The f1 and f2 Difference and Similarity Factors
The f1 and f2 factors were used to compare the release 
profiles generated for OT from PF-127 gels of different 
concentrations. To assess the discriminatory behavior of 
the release tests evaluated, the 25% formulation was used 
as the reference product, and the results of these analyses 
are summarized in Table 6.
USP Apparatus 1 and 2 were not able to discriminate 
between the dissolution profiles generated for the 20% 
and 25% formulations since the f1 factors were < 15 for 
these comparisons. The f2 factor for the comparison of the 
20% and 25% formulations indicates that the profiles are 
similar, and therefore, it may be concluded that both USP 
Apparatus 1 and 2 are unable to produce data that 
differentiate between formulations. However, the f1 for the 
comparison of the 25% and 30% formulations indicates 
that discrimination is achieved (f1 > 15) for both USP 
Apparatus 1 and 2. However, f2 for the profiles generated 
using USP Apparatus 2 (f2 = 66.6) indicates similarity 
between the release profiles, but the test indicates that 
discrimination is achieved for profiles generated using 
USP Apparatus 1 (f2 = 49.1). 
Data generated using USP Apparatus 3 show that the 
use of this apparatus is able to discriminate between 
different formulations since f1 > 15 and f2 < 50 in all cases, 
indicating that differences were detected when the 25% 
formulation was compared to the 20% and 30% formula-
tions. The use of a dialysis bag with the paddle apparatus 
and the membrane-less diffusion system did not allow for 
Table 2. ANOVA Results and Post Hoc Summary for In Vitro Release Profiles Generated Using USP Apparatus 2.
95% Confidence interval to mean difference
Time (min) Comparison Mean difference Lower limit Upper limit P value Summary
30 20% vs. 25% –6.316 –13.41 0.7769 P > 0.05 Not sig.
20% vs. 30% –1.612 –8.705 5.482 P > 0.05 Not sig.
25% vs. 30% 4.705 –2.389 11.80 P > 0.05 Not sig.
60 20% vs. 25% –0.9969 –11.05 9.052 P > 0.05 Not sig.
20% vs. 30% 5.052 –4.997 15.10 P > 0.05 Not sig.
25% vs. 30% 6.049 –4.000 16.10 P > 0.05 Not sig.
90 20% vs. 25% 5.433 –5.343 16.21 P > 0.05 Not sig.
20% vs. 30% 12.62 1.849 23.40 P < 0.05 Sig.
25% vs. 30% 7.192 –3.584 17.97 P > 0.05 Not sig.
120 20% vs. 25% 7.014 –5.647 19.68 P > 0.05 Not sig.
20% vs. 30% 15.42 2.758 28.08 P < 0.05 Sig.
25% vs. 30% 8.404 –4.256 21.07 P > 0.05 Not sig.
180 20% vs. 25% 10.27 –14.96 35.50 P > 0.05 Not sig.
20% vs. 30% 20.82 –4.411 46.05 P > 0.05 Not sig.
25% vs. 30% 10.55 –14.68 35.78 P > 0.05 Not sig.
240 20% vs. 25% 6.988 –1.476 15.45 P > 0.05 Not sig.
20% vs. 30% 15.15 6.688 23.62 P < 0.05 Sig.
25% vs. 30% 8.164 –0.2997 16.63 P > 0.05 Not sig.
360 20% vs. 25% 1.631 –9.472 12.74 P > 0.05 Not sig.
20% vs. 30% 5.443 –5.661 16.55 P > 0.05 Not sig.
25% vs. 30% 3.812 –7.292 14.92 P > 0.05 Not sig.
480 20% vs. 25% –0.1106 –4.397 4.176 P > 0.05 Not sig.
20% vs. 30% –1.956 –6.242 2.331 P > 0.05 Not sig.
25% vs. 30% –1.845 –6.132 2.441 P > 0.05 Not sig.
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discrimination between all formulations tested since f2 
values that were calculated from the relevant release 
profiles were greater than 50, although values greater 
than 15 were obtained for some of the f1 factors. 
Although the three tests that were used to assess 
the discriminatory power of the dissolution methods 
evaluated in these studies produced some conflicting 
results, there is also consensus among the tests. The results 
of these comparisons are summarized in Tables 7 and 8.
A comparison of the different mathematical tools used 
to assess the similarity and difference of the dissolution 
profiles generated using different apparatus indicates that 
there is some consensus among the data. Consensus in 
the results can be observed in Tables 7 and 8, which show 
that the different methods for comparison yield the same 
conclusions for USP Apparatus 1 and 2 in Table 7 and for 
USP Apparatus 1 and 3 in Table 8. The difference in 
sensitivity of the dissolution methods to assess 
discrimination between dissolution profiles is evident 
when comparing the conflicting results obtained for the f1 
and f2, factors generated for the evaluation of the dialysis 
tube and the membrane-less diffusion methods. 
Specifically, the f1 test results indicate that a difference 
between the release profiles exists, whereas the f2 factor 
indicates that the release profiles are similar. This is in part 
due to the insensitivity of this particular model-
independent method when comparing dosage forms with 
a relatively low percent API release from the dosage 
unit. The f2 factor was designed for the comparison of 
dissolution profiles that have near complete release of an 
API and only indicates non-similarity between dosage 
forms when the percent released differs by 10% or more. 
Consequently, methods that generate a low percent 
release would be affected by the insensitivity of this 
model, thereby allowing inappropriate conclusions to be 
drawn when less than 10% difference exists between API 
release profiles generated using test methods such as the 
dialysis and membrane-less diffusion methods. 
Although the use of ANOVA has been deemed too 
discriminatory for the comparison of release profiles, these 
studies indicate that there is a general consensus between 
the data generated using ANOVA and those generated 
using the other comparison techniques. Although the use 
of the f2 similarity factor for the membrane-less diffusion 
system indicates that there were no differences between 
the formulation variants tested, the use of ANOVA 
Table 3. ANOVA Results and Post Hoc Summary for In Vitro Release Profiles Generated Using USP Apparatus 3.
95% Confidence interval to mean difference
Time (min) Comparison Mean difference Lower limit Upper limit P value Summary
30 20% vs. 25% 6.236 4.620 7.852 P < 0.01 Sig.
20% vs. 30% 11.93 10.32 13.55 P < 0.001 Sig.
25% vs. 30% 5.699 4.083 7.314 P < 0.01 Sig.
60 20% vs. 25% 14.80 9.749 19.85 P < 0.01 Sig.
20% vs. 30% 27.93 22.88 32.97 P < 0.001 Sig.
25% vs. 30% 13.13 8.080 18.18 P < 0.01 Sig.
120 20% vs. 25% 7.502 5.617 9.387 P < 0.001 Sig.
20% vs. 30% 31.77 29.88 33.65 P < 0.001 Sig.
25% vs. 30% 24.26 22.38 26.15 P < 0.001 Sig.
240 20% vs. 25% –0.09111 –4.318 4.136 P > 0.05 Not sig.
20% vs. 30% 8.688 4.461 12.91 P < 0.01 Sig.
25% vs. 30% 8.779 4.552 13.01 P < 0.01 Sig.
360 20% vs. 25% –0.09111 –4.798 4.615 P > 0.05 Not sig.
20% vs. 30% 5.892 1.186 10.60 P < 0.05 Sig
25% vs. 30% 5.984 1.277 10.69 P < 0.05 Sig.
480 20% vs. 25% –0.09111 –4.798 4.615 P > 0.05 Not sig.
20% vs. 30% 5.892 1.186 10.60 P < 0.05 Sig.
25% vs. 30% 5.984 1.277 10.69 P < 0.05 Sig.
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indicates that there are differences. The f2 factor is based 
on the difference between the relatively low percent 
released, and since the data are close together, the tool 
fails to distinguish between the dissolution profiles for the 
different formulations tested, despite the difference in the 
mean amount released.
CONCLUSIONS
The selection of the appropriate dissolution method for 
use from the different methods evaluated was based on 
the ability of the method to discriminate between 
formulations, ease of use of the method, and possibility for 
optimization of the release test method. 
The basket and paddle apparatus are automated, easy 
to use, and have the potential for modification of API 
release patterns by a use of different pH and rotation 
speeds, yet based on statistical evaluation, are unable to 
discriminate between the dissolution profiles of the 
formulation compositions tested in these studies. The 
dialysis method that was tested in the study provided 
conflicting results with respect to the ability to 
discriminate and therefore was not suitable for evaluating 
OT release from these dosage units. Furthermore, since the 
dialysis method resulted in a low percent API release from 
the dosage form, conflicting results between the f1 and f2 
factors were observed. ANOVA of the membrane-less 
diffusion method results indicates that this method is able 
to discriminate between the formulation compositions 
tested, although the low percent API release resulted in 
conflicting difference and similarity factors. A further 
disadvantage of this method is that it is non-automated, 
making it very tedious to perform and impractical to use 
when testing many formulations. USP Apparatus 3 permits 
discrimination between the formulation compositions 
evaluated. Since the system is automated, convenient, and 
easy to use, multiple formulation compositions can be 
evaluated for their impact on drug release. Furthermore, 
the use of USP Apparatus 3 permits further optimization 
of an in vitro dissolution test method by allowing for 
changes in pH and other in vivo conditions to be 
mimicked over time as API release is monitored. In 
addition, the system allows for an assessment of whether 
such changes in pH or other conditions affect the release 
kinetics of OT from PF-127 gel formulations.
The success of a formulation depends on several factors 
including the knowledge and experience of a formulator 
and the judicious selection of an in vitro release test 
method. Inference of in vivo behavior from an in vitro 
Table 4. ANOVA Results and Post Hoc Summary for In Vitro Release Profiles Generated Using the Dialysis Method.
95% Confidence interval to mean difference
Time (min) Comparison Mean difference Lower limit Upper limit P value Summary
60 20% vs. 25% 1.893 –0.2980 4.085 P > 0.05 Not sig.
20% vs. 30% 2.464 0.2730 4.656 P < 0.05 Sig.
25% vs. 30% 0.5710 –1.620 2.762 P > 0.05 Not sig.
120 20% vs. 25% 1.872 –1.215 4.958 P > 0.05 Not sig.
20% vs. 30% 3.586 0.4989 6.673 P < 0.05 Sig.
25% vs. 30% 1.714 –1.373 4.801 P > 0.05 Not sig.
180 20% vs. 25% 2.755 0.8885 4.621 P < 0.05 Sig.
20% vs. 30% 5.244 3.378 7.111 P < 0.01 Sig.
25% vs. 30% 2.489 0.6228 4.356 P < 0.05 Sig.
240 20% vs. 25% 2.731 –0.9598 6.422 P > 0.05 Not sig.
20% vs. 30% 5.921 2.230 9.612 P < 0.05 Sig.
25% vs. 30% 3.190 –0.5006 6.881 P > 0.05 Not sig.
360 20% vs. 25% 2.695 –3.338 8.728 P > 0.05 Not sig.
20% vs. 30% 6.457 0.4245 12.49 P < 0.05 Sig.
25% vs. 30% 3.762 –2.271 9.795 P > 0.05 Not sig.
480 20% vs. 25% 4.949 –0.4982 10.40 P > 0.05 Not sig.
20% vs. 30% 9.107 3.660 14.55 P < 0.05 Sig.
25% vs. 30% 4.158 –1.289 9.605 P > 0.05 Not sig.
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Table 5. ANOVA Results and Post Hoc Summary for In Vitro Release Profiles Generated Using the Membrane-Less Diffusion Method.
95% Confidence interval for mean difference
Time (min) Comparison Mean difference Lower limit Upper limit P value Summary
30 20% vs. 25% 0.3581 –0. 1599 0.8762 P > 0.05 Not sig.
20% vs. 30% 0.8357 0.3177 1.354 P < 0.01 Sig.
25% vs. 30% 0.4776 –0.04045 0.9957 P > 0.05 Not sig.
60 20% vs. 25% 0.8112 0.2285 1.394 P < 0.05 Sig.
20% vs. 30% 1.884 1.302 2.467 P < 0.001 Sig.
25% vs. 30% 1.073 0.4904 1.656 P < 0.01 Sig.
90 20% vs. 25% 1.446 0.6220 2.269 P < 0.01 Sig.
20% vs. 30% 3.085 2.261 3.909 P < 0.001 Sig.
25% vs. 30% 1.639 0.8155 2.463 P < 0.01 Sig.
120 20% vs. 25% 1.922 1.066 2.778 P < 0.01 Sig.
20% vs. 30% 4.049 3.192 4.905 P < 0.001 Sig.
25% vs. 30% 2.127 1.271 2.983 P < 0.001 Sig.
180 20% vs. 25% 2.348 1.315 3.381 P < 0.01 Sig.
20% vs. 30% 5.238 4.205 6.272 P < 0.001 Sig.
25% vs. 30% 2.890 1.857 3.924 P < 0.001 Sig.
240 20% vs. 25% 2.783 1.711 3.854 P < 0.001 Sig.
20% vs. 30% 6.233 5.162 7.305 P < 0.001 Sig.
25% vs. 30% 3.451 2.379 4.522 P < 0.001 Sig.
360 20% vs. 25% 3.500 1.969 5.030 P < 0.01 Sig.
20% vs. 30% 7.464 5.933 8.994 P < 0.001 Sig.
25% vs. 30% 3.964 2.434 5.495 P < 0.001 Sig.
480 20% vs. 25% 4.211 2.738 5.684 P < 0.001 Sig.
20% vs. 30% 8.839 7.366 10.31 P < 0.001 Sig.
25% vs. 30% 4.627 3.154 6.100 P < 0.001 Sig.
Table 6. f1 and f2 Values for the Different Formulations Using 
the 25% w/w Formulation as the Reference (shaded areas 
indicate discrimination).
20% w/w PF-127 30% w/w PF-127
In vitro release test f1 f2 f1 f2
USP Apparatus 1  9.9 72.8 31.1 49.1
USP Apparatus 2 13.7 72.6 15.7 66.6
USP Apparatus 3 23.3 49.4 26.1 41.9
Dialysis tube 21.9 75.7 19.4 81.6
Membrane-less diffusion 36.6 81.4 43.2 78.9
Table 7. Summary of Comparison of the Mathematical Models 
Used to Compare the 20% vs. 25% Formulations.
ANOVA f1 f2
USP Apparatus 1 X X X
USP Apparatus 2 X X X
USP Apparatus 3 ! ! !
Dialysis tube X ! X
Membrane-less diffusion ! ! X
! Indicates discriminatory behaviour and X indicates failure to 
discriminate
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release pattern of a therapeutic agent must be confirmed 
by way of in vivo testing, and therefore, such studies are 
recommended in prospective research.
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